↓ Skip to main content

American College of Cardiology

Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes A Network Meta-Analysis

Overview of attention for article published in JACC: Heart Failure, September 2018
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (96th percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news
1 news outlet
policy
1 policy source
twitter
124 X users
facebook
1 Facebook page

Citations

dimensions_citation
41 Dimensions

Readers on

mendeley
112 Mendeley
Title
Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes A Network Meta-Analysis
Published in
JACC: Heart Failure, September 2018
DOI 10.1016/j.jchf.2018.05.021
Pubmed ID
Authors

Caroline K. Kramer, Chang Ye, Sara Campbell, Ravi Retnakaran

Abstract

The authors conducted a systematic review and network meta-analysis of placebo-controlled, randomized clinical trials in the post-Food and Drug Administration (FDA) guidance era to formally compare the effects of 3 new classes of glucose-lowering drugs on hospitalization for heart failure (HF) in type 2 diabetes mellitus. The 2008 FDA Guidance for Industry launched an era of cardiovascular outcome trials for new glucose-lowering drugs in T2DM, including glucagon-like peptide (GLP)-1 agonists, dipeptidyl peptidase (DPP)-4 inhibitors, and sodium glucose co-transporter (SGLT)-2 inhibitors. We searched Embase, PubMed, Cochrane Library, and clinicaltrials.gov between December 1, 2008, and November 24, 2017, for randomized placebo-controlled trials, and performed network meta-analyses by Bayesian approach using Markov-chain Monte Carlo to compare the effects of glucose-lowering drugs on risk of HF hospitalization and estimate the probability that each treatment is the most effective. Nine studies were identified yielding data on 87,162 participants. In the network meta-analysis, SGLT-2 inhibitors yielded the greatest risk reduction for HF hospitalization compared with placebo (relative risk [RR]: 0.56; 95% CrI [credibility interval]: 0.43 to 0.72). Moreover, SGLT-2 inhibitors were associated with significant risk reduction in pairwise comparisons with both GLP-1 agonists (RR: 0.59; 95% CrI: 0.43 to 0.79) and DPP-4 inhibitors (RR: 0.50; 95% CrI: 0.36 to 0.70). Ranking of the classes revealed 99.6% probability of SGLT-2 inhibitors being the optimal treatment for reducing the risk of this outcome, followed by GLP-1 agonists (0.27%) and DPP-4 inhibitors (0.1%). Current evidence suggests that SGLT-2 inhibitors are more effective than either GLP-1 agonists or DPP-4 inhibitors for reducing the risk of hospitalization for HF in type 2 diabetes mellitus.

X Demographics

X Demographics

The data shown below were collected from the profiles of 124 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 112 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 112 100%

Demographic breakdown

Readers by professional status Count As %
Other 15 13%
Student > Master 15 13%
Researcher 12 11%
Student > Ph. D. Student 11 10%
Student > Doctoral Student 7 6%
Other 19 17%
Unknown 33 29%
Readers by discipline Count As %
Medicine and Dentistry 46 41%
Biochemistry, Genetics and Molecular Biology 7 6%
Pharmacology, Toxicology and Pharmaceutical Science 6 5%
Nursing and Health Professions 5 4%
Agricultural and Biological Sciences 3 3%
Other 8 7%
Unknown 37 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 78. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 June 2019.
All research outputs
#546,154
of 25,385,509 outputs
Outputs from JACC: Heart Failure
#136
of 1,583 outputs
Outputs of similar age
#11,683
of 345,354 outputs
Outputs of similar age from JACC: Heart Failure
#6
of 30 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,583 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 30.2. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 345,354 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.